Societe Generale Securities the prospect of good recommendations for the pharmaceutical industry borderland

Societe Generale Securities: the good prospects for the recommended consun pharmaceutical Sina App: Live on-line blogger to guide Sina Hong Kong APP: real time market exclusive reference stocks also worth the investment? What’s the problem? Where is the future of the way out? Sina launched the "Hong Kong Hong Kong stocks as well as unattractive" discussion, with a rational and constructive attitude, welcome attention to Hong Kong stocks, concern of the capital market, Hong Kong stocks together for suggestions, seek the Hong Kong stock market tomorrow. Please to hkstock_biz@sina. Continued strong growth in the medium-term results. Consun Pharmaceutical (1681.HK) August 30th announcement in mid 2016 operating results: operating income grew 16.7% to 452 million yuan; gross profit grew 14.8% to 357 million yuan; the net profit increased 20% to 145 million yuan, earnings per share of 0.15 yuan. Income continued strong growth trend, mainly due to the company to further promote the two main products of Niaoduqing particles and acid spray grape amine injection rolling the successful implementation of the market. The field continued to maintain a leading position in the market. In the first half of 2016, the company depth development of market segments, increase the coverage of hospitals, doctors, drug sales to enhance. Renal drugs sales revenue 348 million yuan, representing an increase of 15.05%, which is still the Niaoduqing locomotive sales growth, for 9 consecutive years to maintain the leading position in the modern Chinese medicine oral nephropathy; medical imaging contrast agent sales revenue 67 million yuan, representing an increase of 6.44% over the same period last year, still leading the domestic magnetic resonance imaging contrast agent market the front row.   acquisition of Yulin pharmaceutical, retail terminal layout. In 2015, the company acquired Yulin pharmaceutical and held a 70.74% stake in the company through a series of holdings. The company through the acquisition of OTC will be combined with the extension pattern of company prescription based sales model and Yulin pharmaceutical, reach the cooperative effect of mutual support, complementary, division of labor, is expected in 2018 Yulin pharmaceutical category focus will enter the market sales of the top five.  : our point of view: the first half of the company’s business development is good, the income has been consistently strong growth, stable profitability. The leading products of Niaoduqing particles as well as the integration of the transformation of Yulin pharmaceutical company is a major bright spot. In the future, the growth is still the company’s characteristics, the dominant species will continue to lead the market, OTC business retail terminal will become the focus of future development. The company’s current market capitalization of HK $4 billion 735 million, the company expects 2016 results corresponding to the current share price of about 13-14 times PE, it is recommended that investors pay close attention to.   risk warning: industry policy change; medical insurance directory adjustment; drug price reduction. (both) to enter the Sina financial stocks] discussion相关的主题文章: